Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 379,828
  • Shares Outstanding, K 43,860
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,670 K
  • 36-Month Beta 2.25
  • Price/Sales 79.30
  • Price/Cash Flow N/A
  • Price/Book 4.31

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.75 +11.74%
on 10/23/17
9.40 -7.87%
on 10/30/17
+0.36 (+4.34%)
since 10/17/17
3-Month
5.91 +46.53%
on 09/08/17
9.40 -7.87%
on 10/30/17
+2.42 (+38.78%)
since 08/17/17
52-Week
1.46 +493.15%
on 01/23/17
9.40 -7.87%
on 10/30/17
+6.46 (+293.64%)
since 11/17/16

Most Recent Stories

More News
CymaBay Therapeutics to Present at Three Investor Conferences

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management...

CBAY : 8.66 (+1.64%)
CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 8.66 (+1.64%)
CymaBay Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 8, 2017 / CymaBay Therapeutics, Inc. (NASDAQ: CBAY) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern...

CBAY : 8.66 (+1.64%)
CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will...

CBAY : 8.66 (+1.64%)
CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the...

CBAY : 8.66 (+1.64%)
CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that...

CBAY : 8.66 (+1.64%)
CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting

- Interim phase 2 study results demonstrate the potential for superior efficacy and better tolerability over existing second-line therapy

CBAY : 8.66 (+1.64%)
GO Therapeutics appoints Dr. Robert J. Wills to Board of Directors

GO Therapeutics, a company exploiting new advances in glycoproteomics to develop novel, multimodal first-in-class cancer therapeutics against intractable targets, today announced the appointment of Robert...

JNJ : 138.00 (-0.63%)
CBAY : 8.66 (+1.64%)
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics

If you want a Stock Review on CBAY, CYTX, CYTR, or SRNE then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Monday, benchmark US indices were in bullish...

SRNE : 2.45 (+2.08%)
CYTX : 0.38 (+8.57%)
CBAY : 8.66 (+1.64%)
CYTR : 2.03 (+7.98%)
CymaBay Therapeutics to Present at Two Investor Conferences

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that...

CBAY : 8.66 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 8.94
1st Resistance Point 8.80
Last Price 8.66
1st Support Level 8.46
2nd Support Level 8.26

See More

52-Week High 9.40
Last Price 8.66
Fibonacci 61.8% 6.37
Fibonacci 50% 5.43
Fibonacci 38.2% 4.49
52-Week Low 1.46

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart